Stocks Pfizer Inc


  • Wall Street looks to break out of 2016 slump Thursday, 14 Jan 2016 | 7:15 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks were lower this morning, after Wednesday's severe slide sent Wall Street to its lowest level since late September.

  • Drug pricing is all about balance: CEOs Tuesday, 12 Jan 2016 | 6:10 PM ET
    Leonard Schleifer

    Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.

  • Trading struggling biotech: 4 stocks to watch Monday, 11 Jan 2016 | 7:17 PM ET
    A Merck sign in front of the company's building in Summit, New Jersey.

    Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.

  • CEOs: What's missing in the drug pricing debate Monday, 11 Jan 2016 | 1:57 PM ET
    Novartis CEO, Joseph Jimenez (L), Pfizer CEO, Ian Read (C), and Eli Lilly & Co. CEO Dr. John Lechleiter (R).

    Several factors are being overlooked when discussing drug pricing in the U.S., three pharma CEOs say.

  • The pharma trade Monday, 11 Jan 2016 | 12:13 PM ET
    The pharma trade

    Health care is leading the market lower today. The FMHR traders discuss their best strategy in looking at this group of stocks.

  • Cramer's market anxiety survival guide Thursday, 7 Jan 2016 | 6:34 PM ET
    Investor thinking

    Jim Cramer helps investors manage market anxiety with his tips to making money in a world of fear.

  • Power Play: Betting on large-cap growth this year Thursday, 7 Jan 2016 | 1:17 PM ET
    A pedestrian passes in front of the Pfizer headquarters in New York City.

    Adding large-cap names to your portfolio.

  • Top investor Martin Sass cashes out of bull market Wednesday, 6 Jan 2016 | 5:00 AM ET
    Martin Sass

    Prominent investor Martin Sass is taking a cautious investment stance after being bullish for most of the market run since 2009.

  • *Sanofi and Mannkind terminate deal for Afrezza. LONDON, Jan 5- French drugmaker Sanofi is to stop selling an inhalable insulin developed by Mannkind, following disappointing sales of the product since its launch in February 2015. Rights to Afrezza will revert to Mannkind from Sanofi in the next 90 to 180 days and Mannkind said it was reviewing strategic options...

  • 8 stocks to buy after 2016's rocky start Monday, 4 Jan 2016 | 7:04 PM ET

    Stocks suffered Monday to start 2016, but "Fast Money" traders saw opportunities in the slide.

  • Cramer: Stocks that rally in a Chinese sell-off Monday, 4 Jan 2016 | 6:15 PM ET
    An investor observes stock market at a stock exchange hall on December 14, 2015 in Beijing, China.

    Jim Cramer prepares investors with his shopping list of stocks to avoid and buy amid the worldwide sell-off.

  • Don't let big Dow drop turn you off these stocks Monday, 4 Jan 2016 | 10:56 AM ET
    A trader's reflection on a screen at the New York Stock Exchange.

    There's a case to be made for the Dogs of the Dow, even as stocks start 2016 down. They offer yields that can pay off a mortgage.

  • 2015 in 5 charts Thursday, 31 Dec 2015 | 2:39 PM ET
    Traders work on the floor of the New York Stock Exchange.

    A slower-growing China, diverging central bank actions and a cutthroat battle among global energy producers were themes.

  • Will merger mania continue in 2016? Thursday, 31 Dec 2015 | 11:25 AM ET
    Handshake M&A mergers

    2015 was a record year for mergers. Here's what the research reveals about how 2016 will compare, says Matt Porzio.

  • *Pep Boys up after board finds Icahn's proposal superior. Dec 29- Wall Street rose sharply on Tuesday, elevating the S&P 500 to a modest gain for the year as Amazon and Apple led tech stocks higher. Amazon climbed 2.78 percent and closed at a record high of $693.97.

  • This was the top business story in 2015 Sunday, 27 Dec 2015 | 10:42 AM ET
    China investor stock prices

    Here are the top 10 business stories of the year, in descending order. NBCNews reports.

  • Prosecutors said the trades enabled SAC Capital to make $275 million, making it the most lucrative insider trading case ever charged in the United States. The $10 million class action accord, which requires court approval, follows earlier deals with U.S. authorities in which SAC Capital agreed to pay $1.8 billion and plead guilty following investigations...

  • Campaigners hail Apple shareholder move Thursday, 24 Dec 2015 | 2:20 AM ET
    iPhone cases are pictured on a wall Apple store in the Manhattan borough of New York.

    Apple’s decision to give shareholders a greater say in boardroom appointments is a significant victory, campaigners have said. The FT reports.

  • NEW YORK, Dec 23- A new class of blood thinners that competes with widely used warfarin should get a boost next year when an "antidote" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson& Johnson, and Eliquis, sold by Bristol-Myers Squibb and...

  • The biggest M&A deals of 2015 Wednesday, 23 Dec 2015 | 5:25 AM ET
    Heinz and Kraft Foods to merge.

    2015 has been a record year for mergers and acquisitions (M&A). CNBC looks back at the 10 biggest deals of the year and who advised on them.